Narrative synthesis of published literature
What the Research Says About Trazodone for Insomnia
A look at why trazodone became one of the most common off-label insomnia treatments, and what the general body of research and clinical experience suggests about its effectiveness and limitations for this use.
Published August 8, 2026. Reviewed by our editorial team on August 8, 2026.
Who was studied: Adults with insomnia, across multiple published studies and clinical reviews
Trazodone's role as a sleep aid is one of the more studied examples of off-label prescribing in modern psychiatry. Because it was developed and approved as an antidepressant, its insomnia-specific evidence comes from a patchwork of smaller trials, clinical observation, and comparative studies against other sleep medications and placebo, rather than the large, indication-specific trial programs that FDA-approved sleep medications underwent.
Generally, this body of evidence and decades of clinical use support that low-dose trazodone helps many people fall asleep faster and sleep more soundly, particularly when depression or anxiety-related sleep disruption is also present. It's less clear how it performs specifically for people with insomnia and no coexisting mood disorder, compared with medications developed and studied specifically for that population.
For readers, the practical takeaway is that trazodone's widespread off-label use for sleep is not baseless — it reflects real clinical experience and a body of supportive (if imperfect) evidence — but it also isn't the same as having gone through the FDA's indication-specific approval process the way medications like zolpidem or low-dose doxepin have for insomnia specifically.
Main result: Across published studies and clinical experience, low-dose trazodone is widely reported to reduce time to fall asleep and improve subjective sleep quality for many patients, though effect sizes vary between studies and it has not undergone the same large-scale, indication-specific FDA review process as medications approved specifically for insomnia.
Limitations: Because trazodone was never developed or approved specifically for insomnia, the research base is more fragmented than for FDA-approved sleep medications — combining older, smaller studies, clinical experience, and off-label prescribing pattern data rather than a unified pivotal trial program.
Not medical advice. This summary is educational and does not replace individualized guidance from your prescriber.
